CUP Syndrome-Metastatic Malignancy with Unknown Primary Tumor.

about

CUP Syndrome-Metastatic Malignancy with Unknown Primary Tumor.

Item

http://www.wikidata.org/entity/Q52627096

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

CUP Syndrome-Metastatic Malignancy with Unknown Primary Tumor.

@en

CUP Syndrome-Metastatic Malignancy with Unknown Primary Tumor.

@nl

type

Item

label

CUP Syndrome-Metastatic Malignancy with Unknown Primary Tumor.

@en

CUP Syndrome-Metastatic Malignancy with Unknown Primary Tumor.

@nl

prefLabel

CUP Syndrome-Metastatic Malignancy with Unknown Primary Tumor.

@en

CUP Syndrome-Metastatic Malignancy with Unknown Primary Tumor.

@nl

P1476

CUP Syndrome-Metastatic Malignancy with Unknown Primary Tumor.

@en

P2093

Andrea Tannapfel

http://www.w3.org/2001/XMLSchema#string

Gregor Zaun

http://www.w3.org/2001/XMLSchema#string

Ken Herrmann

http://www.w3.org/2001/XMLSchema#string

Martin Schuler

http://www.w3.org/2001/XMLSchema#string

P2860

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

Cancer of unknown primary site

Pembrolizumab for the treatment of non-small-cell lung cancer

Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial.

18F-FDG PET/CT for detection of the primary tumor in adults with extracervical metastases from cancer of unknown primary: A systematic review and meta-analysis

Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis.

Carcinoma of Unknown Primary - an Orphan Disease?

Patients with cancer of unknown primary: a retrospective analysis of 223 patients with adenocarcinoma or undifferentiated carcinoma

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial.

P304

157-162

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3238/ARZTEBL.2018.0157

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

115Background: 2-4% of newly diagnosed cases of maligna

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29587959

http://www.w3.org/2001/XMLSchema#string

P932

5881077

http://www.w3.org/2001/XMLSchema#string